FIGURE 6.

KRIBB11 inhibits the growth of HCT-116 cells in a nude mouse xenograft regression model. A, for the evaluation of the in vivo anti-tumor activity of KRIBB11, HCT-116 cells were implanted subcutaneously into the right flank of nude mice on day 0. Compounds were dissolved in 10% dimethylacetamide, 50% PEG300, and 40% distilled water and were administered intraperitoneally for 18 days at a concentration of 50 mg/kg for KRIBB11 or 2 mg/kg for adriamycin per day. The results shown were obtained from one assay using 18 mice (six mice for each compound). Tumor volumes were estimated by the formula length (mm) × width (mm) × height (mm)/2. B, body weight was measured on each indicated day. C, lysates were prepared from tumor tissues of six mice for each compound, and whole cell lysates were analyzed by Western blotting as described under “Experimental Procedures.” Statistical significance (p value) was determined with an unpaired t test. *, p < 0.05 versus control; ***, p < 0.001 versus control.